New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Moderna, Inc.

MRNA

Healthcare Biotechnology

Moderna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.9 billion, down 39.9% from fiscal 2024.

Revenue
+29.2%
EPS
n/m
Free cash flow
n/m
Total debt
+13,550.0%

Quarter to September 2026, against a year earlier

195.12 4.21 −2.11%

After hours trading: 199.30, up 2.14%, last trade Fri 7:57pm Eastern.

Market cap
$79.6B
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
3/9
ROIC
−35.1%
Net debt / EBITDA
1.8×
Payout ratio
—

Revenue to profit Q3 FY2026, quarter to Sep 30, 2026

Of every $100 of revenue, $12.34 was left as profit. Gross margin has risen two quarters running, from −145.5% to 75.8%. What is an income statement?

Revenue to profit, in billions of dollars and as a share of revenue
Revenue1.3100.0%
Cost of revenue−0.3−24.2%
Gross profit1.075.8%
Research & development−0.6−44.4%
Selling, general & admin−0.3−21.5%
Operating income0.19.9%
Other income, net0.03.1%
Income tax0.0−0.7%
Net income0.212.3%
RevenueOperating incomeNet incomeNet margin (right axis)
Revenue, operating income and net income, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Revenue$678M$389M$145M$1.3B
Operating income−$857M−$1.4B−$815M$130M
Net income−$826M−$1.3B−$782M$162M
Net margin (right axis)−121.8%−345.2%−539.3%12.3%
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Revenue
1,313.00 145.00 389.00 678.00

+8 more quarters

Revenue Growth
29.23% 2.11% 260.19% (29.81%)
Cost of Revenue
318.00 93.00 955.00 452.00
Gross Profit
995.00 52.00 (566.00) 226.00
R&D Expenses
583.00 651.00 649.00 775.00
SG&A Expenses
282.00 216.00 173.00 308.00
Operating Income
130.00 (815.00) (1,388.00) (857.00)
Non-operating Income/Expense
41.00 48.00 54.00 58.00
EBT
171.00 (767.00) (1,334.00) (799.00)
Income Tax Provision
9.00 15.00 9.00 27.00
Income after Tax
162.00 (782.00) (1,343.00) (826.00)
Net Income Common
162.00 (782.00) (1,343.00) (826.00)
EPS (Basic)
0.40 (1.97) (3.40) (2.11)
EPS (Diluted)
0.38 (1.97) (3.40) (2.11)
Shares (Basic, Weighted)
401.00 398.00 395.00 389.00
Shares (Diluted, Weighted)
430.00 398.00 395.00 389.00
Gross Margin
75.78% 35.86% (145.50%) 33.33%
EBIT Margin
9.90% (562.07%) (356.81%) (126.40%)
EBT margin
13.02% (528.97%) (342.93%) (117.85%)
Net Profit Margin
12.34% (539.31%) (345.24%) (121.83%)
EBITDA
186.00 (762.00) (1,340.00) (803.00)
EBIT
130.00 (815.00) (1,388.00) (857.00)
Income from Continuous Operations
162.00 (782.00) (1,343.00) (826.00)
Consolidated Net Income/Loss
162.00 (782.00) (1,343.00) (826.00)
EPS (Basic, from Continuous Ops)
0.40 (1.96) (3.40) (2.10)
EPS (Diluted, from Cont. Ops)
0.38 (1.96) (3.40) (2.10)
EPS (Basic, Consolidated)
0.40 (1.96) (3.40) (2.10)
EPS (Diluted, Consolidated)
0.38 (1.96) (3.40) (2.10)
Shares (Diluted, Average)
430.00 398.00 395.00 392.00
EBITDA Margin
14.17% (525.52%) (344.47%) (118.44%)
Operating Cash Flow Margin
(118.74%) (362.76%) (161.95%) 137.17%

Fold the line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 11, 2026